Tr eatment with vitamin Kantagonists (coumarins)isassociated with an increasedr isko fb leeding. In ordert oe lucidate the bleeding riskofusers of antiplateletdrugs amongusers of coumarins, we assessedthe odds ratio of major bleeding associated with use of antiplateletdrugs in usersofthe coumarins acenocoumarol and phenprocoumon.We used datafromaDutchrecordl inkages ystem,i ncluding pharmacy andl inked hospitalizationrecords forapproximatelytwo million subjects,to conduct anestedcase control study in acohortofnew usersofcoumarins. Caseswerepatientswho were hospitalizedwith aprimary diagnosis of major bleeding while taking coumarin and were matchedw ith up to four control subjects.Conditional logistic regression analysis was usedtodetermineORs and 95%confi-Keywords Drug interaction, bleeding, coumarins, antiplateletdrugs dence intervals (CI).Weidentified 1848 case patients who were matchedt o5 818 controls. Users of clopidogrelo ra spirin showed asignificantly increasedrisko fhospitalization because of major bleeding (OR 2.9, 95%CI1.2-6.9 and OR 1.6, 95%CI 1.3-1.9, respectively),whereas users of dipyridamole and combinationsofantiplatelet drugs showed astrong trend (OR 1.5,respectively).Inall cases,the risksweregreaterfor uppergastrointestinal bleedings than forotherbleedings.Inconclusion,theuse of anyantiplatelet drugi ncreasest he risk of hospitalizationf or major bleeding among users of coumarins. Concurrent useofclopidogrelordipyridamoleand coumarins is probablynot safer than concurrent useofaspirin and coumarins.
Introduction
Coumarins are effective drugs for the prevention of venous and arterial thromboembolism.The most common indication is atrial fibrillation for whicht he therapeutic superiority over aspirin aloneo rac ombination of the antiplateleta gents aspirin and clopidogrel has been firmly established ( 1) . The principal adverse effect of therapywith anticoagulants of the coumarintype is major bleeding,which canbefatal or disabling. Recently,the risk factorsf or increased bleeding in users of coumarins have beensystematicallyreviewed (2, 3) . This increased bleeding risk is an inevitablec onsequence of the pharmacodynamics of the coumarins, whichaffect the coagulation cascade by interfering with the activation of clotting factorsII, VII, IX and X, ultimately inhibiting the formation of fibrin.
Antiplatelet drugs interferew ith the activation of platelets and are of major importanceinthe prevention of atherothrombosis in patients suffering from atherosclerosis. There is ample evidencefor the effectiveness of antiplatelettherapyinpreventing recurrent vasculare vents in cerebrovasculard isease, coronary artery disease and peripheral arterydisease (4, 5) .
With the increasing useofantiplatelet agents, the incidence of concurrent use with coumarin anticoagulants is expected to increase, for exampleinpatients sufferingfrom atrial fibrillation after coronarys tent placement or after acutec oronary syndromes. However, in dailypractice aspirin is frequently added to acoumarin for associated stable vasculardisease, although there is no evidencefor benefitofsuch acombination, whereas it is plausible thatitwill be harmful (6) . This underlinesthe needfor reliable information on the bleeding risk of combined useofantiplateletdrugs and coumarins comparedtocoumarins alone.
Because of the different pathwaysa long whichc oumarins and antiplateletd rugs affect haemostasis, an increased major bleeding risk with concurrentuse compared with use of coumarins alone is conceivablefor all antiplateletdrugs. Forconcurrent use of aspirin with coumarins such an increased bleeding risk has been convincingly demonstrated in several clinical trials (7) (8) (9) (10) (11) , meta-analyses (12,1 3) and population basedo bservational studies (14) (15) (16) (17) . However, the effect of the newera ntiplatelet drugs clopidogrel and dipyridamoleonthe bleeding risk among users of coumarins is unkown. Fordipyridamole conflicting results have beendescribed (18, 19) , whereas to date no data have beenr eported on the risk of concurrent useo fc lopidogrel and coumarins.Toestablish the effect on the bleeding risk of clopidogrel and dipyridamoleamong users of coumarins,weconducted apopulation-based case-control study within acohortofusers of the coumarinantagonists acenocoumarol and phenprocoumon.
Materials andmethods

Designand setting
We conducted acase-controlstudy in acohortofnew usersof acenocoumarol or phenprocoumon,t he twoc oumarin anticoagulants licensedinThe Netherlands. The setting of the study wasthe PHARMO recordlinkage system(PharmoInstitute, Utrecht, The Netherlands; availablea th tpp://www.pharmo.nl). This systemi ncludest he demographic details and complete medication histories from community pharmacies formore than twom illion community-dwelling residents in 25 geographic areas in TheN etherlands from 1985 to the present dayf urther linked to hospital admission records. Because virtuallya ll patients in TheNetherlands are registered with asingle community pharmacy, pharmacyrecords are essentiallycomplete insofar as the prescription drug use is concerned. Forthis study,drugprescribing dataa nd hospitalization data were used. Drugsa re coded according to the Anatomical Chemical Therapeutic Classification (ATC). Theh ospital admission and dischargec odes arec oded according to the InternationalC lassification of Diseases,Ninth Revision, Clinical Modification (ICD-9-CM).
Cohortand exposuretocoumarins
In the cohortofnew usersofone of the coumarin anticoagulants, all patients aged18years and above whohad receivedafirst prescription foracoumarin betweenJanuary1,1991 and December 31, 2004, and whodid not have ahistoryofhospital admission for major bleeding prior to coumarinstart,were included. Apatient wasdefinedasanew coumarinuserifnone of these drugs had beendispensedbefore the first coumarindispensinginthe PHARMO database and if amedication history for at leastone year beforei nitiation of the coumarin anticoagulant wasa vailable.P atients were followedu pu ntil hospital admission for major bleeding,end of data collection (for exampleincaseofremovalofpatient to an area outside the area of the PHARMO database), deathordiscontinuation of coumarintherapy, whichever occurredfirst.
Prescriptions for coumarinanticoagulants do not contain information about the dosage,which is variable and is frequently adjustedb yanticoagulation clinics. As aresult, the duration of coumarinuse cannot be calculated fromthe number of dispensed units and the prescribed dosage.Weassumedthat treatment was discontinuedifmore than 180 days had elapsed after the last recordedd ispensingd ateo fa cenocoumarol or phenprocoumon. Theperiod of 180dayshas been estimatedonthe basis of experienceindaily practice.Coumarin anticoagulants areusuallydispensedi nl arge quantities( several hundred definedd aily dosages) and because dailyd osagess howl arge interindividual variation,180 days could be an underestimation or an overestimation of the duration of use.
Cases and controls
Casesw ere allp atients with af irst hospitalization for major bleeding while being treated with acoumarin. To identifymajor bleeding we used InternationalClassification of Diseased,Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes, whichcover the classification of major bleedingsdescribed by Fihn et al. for complications of anticoagulant treatment (20) (see Appendix Table1 )T he date of first hospitalization for major bleeding wasconsideredtobethe indexdate. Foreach casepatient, up to fournonhospitalizedcontrols were randomly selected from the cohortb yr isk-sets ampling. Control subjectsw ere matchedw ith casep atients for sex, age (± 5y ears), coumarin anticoagulant (acenocoumarol or phenprocoumon), time since initiation of coumarintherapy(±90daysfrom dispensing date) and geographic region,and were assignedthe same indexdateas the corresponding casepatient.
Definitionofexposure
We analyzed the followingap riori chosen antiplateletd rugs: clopidogrel (ATC codeB 01AC04), dipyridamole (ATC code B01AC07) and low-dose aspirin (30-100 mg) (ATC codes B01AC06 and B01AC08). Since antiplateletagents canbeused concurrently (21) (22) (23) (24) , and since such combinations could carrya morei ncreased bleeding risk (21) (22) (23) ,w es eparatelya nalyzed use of aspirin, clopidogrel and dipyridamolealone or use of these drugs in combination (including the fixedcombination of aspirin +dipyrimole,A TC code B01AC30). In the PHARMO database theduration of use of adispenseddrugiscalculated by dividing the number of dispensed units by the prescribed numbert ob e used per day. If the duration of use extendedwith 10% ended on or beyond the indexdate, this wasconsideredtobethe current use of the antiplateletdrug. If the duration of use extendedwith 10% from adispensingdateended within 30 days or more than 30 days before the indexdate, it wasconsideredasrecent useor past use, respectively.
Potential confounders
As potentiallyc onfounding comedication we defined current use of non-steroidal anti-inflammatorydrugs (NSAIDs) (selective COX-2-inhibitors were noti ncluded, because their association with bleeding is less clear thanf or nonselective COX-2-inhibitors), selective serotonin reuptake inhibitors(SSRIs),glucocorticoids,known inhibitors of coumarin metabolism (25-27) (amiodarone,allopurinol, benzbromarone, miconazole, fluconazolea nd gemfibrozil), known inducers of coumarin metabolism(25, 27) (carbamazepine, phenytoin, phenobarbitone and rifampicin) and antibiotics (asaproxy for intercurrent infections). Moreover,u se of gastroprotective agents (proton pump inhibitors, H2 receptor antagonistsand misoprostol) wasdefined as potentiallyconfounding or effect modifying comedication for upper gastrointestinal bleeding.F or current use of confounding or effect modifying comedication, we used the same definitions as for antiplateletagents. Anyuse before the indexdateofthyroidtherapy, antidiabetic drugs,a ntineoplastic agents and ac ombination of ACEi nhibitors or angiotensin II antagonistsw ith loop diureticsw ere proxiesfor thyroid diseases, diabetes mellitus, malignancies and heart failure, respectively.
Statisticalanalysis
We compared the use of antiplateletd rugs betweenc ases and controls. So, sincethe cohortconsisted of usersofcoumarins, we compared concomitant use of coumarins and antiplateletdrugs in the case group with concomitant use of coumarins and antiplatelet drugs in the control group. We used conditional logistic regression models on the matchedsetstoestimate the risk of bleeding associatedwith currentuse of antiplateletagents, expressed as odds ratios (ORs) with 95% confidenceintervals (CIs).
We analyzed allmajor bleedings. Moreover, we stratified our analyses by upper gastrointestinal and nonupper gastrointestinal bleedings(designated as 'otherbleedings'),becausethese bleedings have different prognosticfactorsand because we expected that at least the use of aspirin would be more associated with upper gastrointestinal bleeding thanw ith otherb leedings. We separatelyanalyzedclopidogrel, dipyridamole, lowdose aspirin and all combinations of these antiplateletagents.
Within the stratum of upper gastrointestinal bleedingsw e also analyzed whether an effect of antiplateletagents wasmodified by gastroprotective drugs. We separatelya nalyzedo ur resultsfor usersofacenocoumarol and phenprocoumon.
In sensitivity analyses we reanalyzed ourr esults on the assumption thatcoumarin use endedamaximum of 30, 60 or 90 days (rather than180 days) after the last dispensing date and for usersw ho received moret han one prescription for ac oumarin anticoagulant. Moreover,wereanalyzed ourresults for bleeding eventsthat occurredafter the first 28 days of coumarinuse,in- creasing the chance thatpatients are moreorlessstabilized becausethe initiation phase canbeassociatedwith problems such as dose finding and severe overanticoagulation. We also analyzed ourdatafor recent and past use of the examineddrugs. All statisticala nalyses were performed using commercially available software (SPSS, version 12;SPSS Inc, Chicago,IL, USA).
Results
We identified70,201 patients whowere treated with acoumarin, for atotal of 131,707 patient years.Within this cohortweidentified 2403 cases of first bleeding requiring hospitalization (incidence rate 1.82 per 100patient years). Of these,555 could not be matchedt oc ontrol subjects, leaving 1848 cases availablef or analysis, whow ere matchedw ith 5818c ontrol subjects. The median follow-up timeinpatients until bleeding was220 days (range:1-4690 days). Meanage at the indexdatewas 72.7 years, there were morem en thanw omen; and almost 90% of the patients used acenocoumarol ( Table 1 ). The most frequentlyoccurring bleeding wasupper gastrointestinal bleeding (n=537), followedbyintracranialbleeding (n=318)(Table2). Daily dosagesofaspirin rangedfrom 30 to 100 mg for most patients (4 outof536 aspirin usershad adaily dosage of 160 mg). No patients used aspirin continuouslyi nd aily dosagesh igher than160 mg. Dailydosagesofdipyridamole ranged from 150to 450 mg and the dailydosage of clopidogrel was75mginall patients.
When major bleeding occurred (upper gastrointestinal and other bleedingst aken together) the risksw ere significantlyi ncreased for clopidogrel aloneand for aspirin alone,multivariate ORsbeing 2.9(95% CI 1.2-6.9) and 1.6 (95% CI 1.3-1.9), respectively.The risks for dipyridamole and combinations of antiplateleta gents were alsoi ncreased for all bleedings, although just not significantly,m ultivariate ORsb eing 1.5( 95% CI 1.0-2.3) and 1.8 (95% CI 1.0-3.3) ( Table 3) .
Use of all antiplateletagents, including clopidogrel and dipyridamole, increased the risk of upper gastrointestinal bleeding. Thepoint estimate washighest for clopidogrel,the effect showing as trong trend towards significance (OR 3.6, 95%C I 0.9-13.5) ( Table 3) . Use of gastroprotective drugs did not modify the effect of antiplateleta gents on the outcome upper gastrointestinal bleeding.
Useofantiplatelet drugs increased the risk of other bleedings to alessere xtent. The use of onlyaspirin wassignificantly associatedwith an increased risk of other bleedings. The use of dipyridamoler esultedi nas imilarp oint estimate, whereas the pointestimate forclopidogrel wasgreatest, as it wasfor upper gastrointestinal bleedings(Table3).
Separate analysis of the most invalidating categoryofbleedings,t he intracranial bleeding,r esultedi nn ot significantly increased risks fora spirin and dipyridamole, (adjustedO Rs 1.2, 95%CI0.7-2.0 and 1.6, 95% CI 0.6-4.2, respectively), point estimatesbeing roughlysimilartothe point estimates for all non upper gastrointestinal bleedings. Foru sers of clopidogrel or combinations of antiplateletd rugs numbersw ere too lowf or analysis.
Separate analysis for users of acenocoumarol resultedi n similar point estimatesasfor the pooled analysesofusers of acenocoumarol and phenprocoumon.U se of aspirina nd dipyridamole resulted in somewhat higher point estimatesi nu sers of phenprocoumon, although the ORs compared with users of coumarins alone were notstatistically significant (OR2.3, P-value 0.10 and 2.5, P-value 0.10, respecively).Arisk estimate wasnot possible for clopidogrel (N=2). Sensitivity analyses didnot change the overallpictureofour results, with the risks remaining higher for upper gastrointestinal thanf or other bleedings. Fora spirin, the results foru pper gastrointestinal and other bleedingsa re presented in Table4 .F or other antiplateletdrugs the numbersbecamelower,resulting in wider confidenceintervals without changing the pictureofour main findings (data not shown).
Past use of allantiplatelet drugs did not showsustained increased bleeding risks (univariate ORsfor all bleedingstogether 1.0, 1.0a nd 1.2 for aspirin, clopidogrel and dipyridamole, respectively,point estimates being similar for upper gastrointestinalbleedings[data not shown]). Recent use showedatendency foranincreased bleeding risk in users of aspirin(OR 1.4,P-value 0.08 for all bleedingsand OR 1.5, P-value 0.31 for gastrointestinalbleedings), while the numbers of recentusers of clopidogrel (N=5) and dipyridamole(N=10) were too small for analysis.
Discussion
This study demonstrated for the first time thatinusers of coumarins clopidogrel increases the risk of major bleeding at leastas mucha sa spirin. Ford ipyridamole we also found an increased risk approaching statistical significance.
Theresults of our studyregarding aspirinare in agreement with the results of otherp opulation baseds tudies (14) (15) (16) (17) and with the findings of arecent meta-analysis by Salemetal., which assessedt he therapeutic benefits and risks of combined useo f aspirina nd coumarins comparedw ith use of coumarins alone (12) , their OR for increased major bleeding risk (1,4 3) being exactly the same as ours.
Although one studyshowednoeffect of clopidogrel on INR amongp atients receiving long-termw arfarint herapy ( 28) , whichsuggests the absence of apharmacokinetic interaction, a pharmacodynamic interaction betweenclopidogrel and coumarins is conceivablebecauseoftheir differing effects on haemostasis. Clopidogrel is increasingly used as an antiplateleta gent, with one trial suggesting that it wasmore effective and caused significantlylessgastrointestinalbleeding thanlow dose aspirin (325 mg daily) (29) .However,intwo studiesamong high risk patients with ah istoryo fu pper gastrointestinal complications, clopidogrel wasassociatedwith ahigh incidenceofupper gas- trointestinalbleeding (30, 31) . Oneofthese studies even demonstrated thatthe combined use of aspirin and aproton pump inhibitorwas superior to clopidogrel in the prevention of recurrent ulcer bleeding (30) .I naD anish population-based casec ontrol study,c lopidogrel alone wasn ot associated with an increased risk of upper gastrointestinal bleeding,whereasthe combination with aspirin increased the bleeding risk beyond the effect of aspirin alone (17) .The findings of our study similarlysuggest that clopidogrel addstoafurtherincreased bleeding risk amongusers of coumarins and thatclopidogrel is not safer thanlow dose aspirin when used in combination with coumarins,this suggestion being stronger for upper gastrointestinal bleedingsthan for other bleedings. Whilst it is not surprising thatthe combination therapywith warfarin,aspirin and clopidogrel wasassociatedwith a significantly increased risk of major bleeding compared to therapyw ith aspirina nd clopidogrel (32),t oo ur knowledge our study is the first to demonstrateanincreased bleeding risk forthe concurrent use of clopidogrel (withouta spirin) and coumarins compared with coumarins alone. Publisheddataonthe effect of dipyridamole on bleeding risk amongu sers of coumarins are contradictory. Massele ta l. reported an increased bleeding risk in ameta-analysis amongpatients with prosthetic heartvalvesfor the combined use of dipyridamole and coumarins comparedt oc oumarins alone (19) , whereas Pouleur et al. did not find an increased risk in another meta-analysis (18) Our results are in agreement with the findings of Masseletal., whoprimarily analysed major bleedingsasw e did. Although dipyridamole, unlikeaspirin, doesnot inhibitthe synthesis of gastroprotecting prostaglandins (33) ,aD anish population-based observationals tudy found as imilarlyi ncreased risk of upper gastrointestinal bleedingsi nu sers of dipyridamolealone and lowdose aspirin alone (17) ,which agrees with our finding that dipyridamole increases the risk of upper gastrointestinal bleedingstothe same extent as lowdose aspirin among usersofcoumarins.
Our resultss trongly suggest thata ll antiplateletd rugs increase the risk of upper gastrointestinal bleedingsmore than the risk of other bleedings. This wasexpected for aspirin because of its irreversibleand unselective inhibition of cyclo-oxygenase-1 (COX-1), whichhas arole in the protection of the stomachmucosa (34) .However,inusers of coumarins the risk increasing effect of other antiplateletdrugs does not seemtobedifferent from the risk increasing effect of lowdose aspirin in the dosage range from 30-160 mg.
Our study has several limitations.First, there is the possibility of misclassification of users of coumarins,becausewehad to make assumptions regarding the duration of coumarinuse.However,areduction of the maximum time between the last dispensing date and the indexdatedid not result in essentiallydifferent outcomes, suggesting thatour assumptions were justified. Asecondlimitation is thatwedid not have data on the intensityofanticoagulation (normal or high) or on diseases that we could not derive from drug therapy, sucha sl iver and renal insufficiency, whichare alsorisk factorsfor major bleeding (27, 35) . Athird limitation is that we could onlyevaluate ahistoryofhospitalization for major bleeding fromthe moment patients were included in the PHARMO record linkage system, implicating thatw e could have missedi nformation about earlier bleedingsi np atients. Aforth potential limitation is that it is possible that use of confounding over-the-counter-drugs (OTC drugs, such as as- we do not think that lackofsuch information canhaveseriously confounded ourresults. Finally, the database containedneither information about the indications for useofcoumarin anticoagulants, nor for the combined use with antiplateletagents. We know from our other studies in Dutch populations that atrial fibrillation is the commonest indication for coumarins in outpatients (36, 37). However, we can only speculateonthe reasons for combining acoumarin with an antiplateletdrug, whichprecludes a judgement on the potentialappropriateness of combined use. The resultsofour study give rise to some clinical considerations.Guidelines of the AmericanCollege of Chest Physicians recommend adding dipyridamole or clopidogrel to warfarin in situations in whichacombination of warfarin and an antiplatelet agentisindicated and patients areunable to takeaspirin (38, 39) . Of course, the desirability of combining coumarins and antiplateletdrugs is amatterofconsiderabledebateand the benefit-risk ratiof or applying such combinations is still unclear,e venf or situations in whichc ombined use seems rational (6, 40) . Anyhow, our findings do not supportthe viewthat adding clopidogrel or dipyridamoletocoumarins is safer than adding lowdose aspirin to coumarins.
In summary, our resultss uggest that next to aspirin, both clopidogrel and dipyridamoleincrease the risk of major bleeding amongusers of coumarins,and that this risk is more increased for upper gastrointestinal bleedingsthan for anyotherbleedings.
